The DABOM

Pipeline

PipelineR&D schedule

Liquid biopsy is a diagnostic method using body fluids, and it is the less invasive and the safer method than the tissue biopsy, which collects tumor tissue, and can be tested multiple times.
In the blood of cancer patients, various cancer-related circulating biomarkers (CB) such as circulating tumor cells (CTC), exosomes, and circulating tumor DNA (ctDNA) exist in the blood of cancer patients.
Since these circulating biomarkers represent the characteristics of cancer tissues, they are necessary for cancer diagnosis and establishment of treatment strategy.
The DABOM Corp. is developing products related to early diagnosis, companion diagnosis, and metastatic cancer diagnosis of various cancer types based on independent circulating biomarker separation and analysis technology.
The vast results that can be obtained through The DABOM's products are analyzed through machine learning (ML) techniques to ensure high sensitivity and accuracy.

Liquid biopsy-based diagnostics
	2022				2023				2024				2025
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Biomarker isolation system
Early diagnosis of breast cancer
Companion diagnosis of breast cancer
Expand to 5 cancer types

After the COVID 19 pandemic, there are increasing demands for an all-in-one type diagnostic kit that can determine whether or not someone is infected in a timely manner, anywhere.
The all-in-one type diagnostic kit is based on the concept of Sample-to-Answer, and the results can be checked immediately without any additional processing by adding body fluids to the kit.
The DABOM Corp. is developing products, that can determine whether infected or not without going to a hospital, by using its own sample pre-processing technology and know-how in the production of rapid diagnostic kits.